Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections.
Prolonged erections, priapism, secondary to pharmacologic stimulation are usually treated by drainage of the corporeal bodies and irrigation with a sympathomimetic. To study the efficacy of oral medical therapy in the treatment of priapism, 75 patients with pharmacologically induced (prostaglandin E1) prolonged erections were randomized to receive terbutaline, pseudoephedrine, or placebo. Detumescence occurred in 36 percent, 28 percent, and 12 percent, respectively. Terbutaline was significantly better than placebo (p < 0.05) in achieving detumescence. The results of this study suggest that oral terbutaline should be considered in the initial management of pharmacologically induced prolonged erections.
Department of Urology, St. Luke's/Roosevelt Hospital Center, New York, New York.
F C
FC
Lowe
J P
JP
Jarow
D000527:Alprostadil / Q000009:adverse effects* / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D004809:Ephedrine / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D011317:Priapism / Q000139:chemically induced / Q000188:drug therapy*; D012964:Sodium / Q000627:therapeutic use; D017693:Sodium Bicarbonate; D013726:Terbutaline / Q000627:therapeutic use*
D001639:Bicarbonates; D017693:Sodium Bicarbonate; D012964:Sodium; D000527:Alprostadil; D004809:Ephedrine; D013726:Terbutaline